El intrépido tridente de guitarras clásicas estrenó su más reciente trabajo discográfico con el que Mangoré atravesó el ...

Moderna (MRNA) has clearly outperformed after announcing an Oct. 24 presentation that will include additional late-stage trial data for its cancer shot developed with Merck (MRK), even as analysts ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase the rally, there are some uncomfortable numbers ...

Lin-Manuel Miranda wrote the music, lyrics, and book for Hamilton—and starred in the title role. Now imagine if he’d also directed, choreographed, and served as lead producer, and you get a sense of ...

Durante la partita del campionato di seconda divisione brasiliano tra Operário e Goias, Felipe Clemente, calciatore del Goias, segna con un colpo di tacco al volo. Clemente raccoglie un cross a centro ...

DES PLAINES. Ill. (WLS) -- Tony Danza is a beloved actor who was first known in the wildly popular sitcoms "Taxi" and "Who's the Boss?" Now, he's got a live show called "Standards & Stories," with ...

Moderna stock has surged nearly 600% this year on a cancer vaccine trial result that almost no one outside the trial has actually seen in full. What happens when Madrid finally puts the complete data ...

La Municipalidad de Asunción, a través de la Dirección General de Cultura y Turismo y su Dirección de Acción Cultural Comunitaria, invita a toda la ciudadanía a sumarse este viernes a una gran previa ...

After nearly quadrupling over the past month, it's time to get out of Moderna (MRNA) stock, a Citi analyst said Wednesday as he downgraded shares to a sell rating. Citi's Geoff Meacham's downgrade ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Mary Roeloffs is a Forbes breaking news reporter covering pop culture. Citigroup analyst Geoff Meacham downgraded Moderna from a neutral position and raised Citi’s price target on the stock from $60 ...

After rallying almost seven-fold this year, Citi is now advising clients it’s time to get out of Moderna. Its healthcare team, led by global head Geoff Meacham, has downgraded the pioneering biotech ...